| Website | oxfordimmunotec.com |
| Blog | facebook.com/home... |
| @TBDiagnosis | |
| Category | BioTech |
| Phone | +44(0)1235 442780 |
| marketing@oxfordi... | |
| Employees | 79 |
| Founded | 2002 |
| Description | TB Testing Company |
| TOTAL | $107M |
| FUNDING TOTAL | $107M |
| Series B, 8/05 Prelude Trust Quester Capital The Dow Company | £7M |
| Series C, 10/07 Clarus Ventures Wellington Partners NTEC Prelude Trust Quester Capital The Dow Company | $40M |
| Series D, 5/10 New Leaf Venture Partners Kaiser Permanente Ventures Clarus Ventures Wellington Partners Spark Ventures DFJ Esprit Oxford University | $26M |
| Venture Round, 6/12 Imperial Innovations Invesco Perpetual Clarus Ventures New Leaf Venture Partners DFJ Esprit Wellington Partners Spark Ventures Kaiser Permanente Ventures | $28M |
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company’s first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).
